The Company's Lead Cancer Drug
AntiRadical Therapeutics LLC (ART) is dedicated to the development of a superoxide dismutase mimetic as an anti-metastasis drug to reduce mortarlity and to improve quality of life of cancer patients. ART has demonstarted the preclinical efficacy of VACNO [(vascular albumin with caged nitric oxide aka PNA (polynitroxylated albumin)] in multiple cancer models, including triple negative breast cancer (TNBC) and brain cancer. The work on TNBC was recently published. VACNO is a macromolecular superoxide dismutase mimetic - its activity is dervived from conjugated nitroxides as shown below.
VACNO has been demonstrated to have five (5) therapeutic mechanisms in the triple negative breast cancer model:
1) Removes the superoxide and related reactive oxygen species to prevent metastasis
2) Improves the blood flow to the tumor hypoxic core, which improves standard cancer therapies (potentially including immunotherapy)
3) Reverses metastasis that results as a side-effect of chemotherapy (certain chemotherapeutic drugs, such as dexamathazone, induce superoxide formation and cause metastasis)
4) VACNO serves, like albumin, as a carrier for paclitaxel, the most widely used anti-mitosis drug employed in cancer therapy
5) VACNO was found to extend survival when used conjunctively with 3 standard chemotherapeutic drugs, with corresponding inhibition of metastasis.
Recently published work: "Use of Antimetastatic SOD3-Mimetic Albumin as a Primer in Triple Negative Breast Cancer" SM Messerli et al., Journal of Oncology 2019 https://doi.org/10.1155/2019/3253696
The current preclinical efficacy data supports the initiation of Phase Ib clinical trial after approval of Investigational New Drug (IND) status by FDA. VACNO has completed GLP IND safety study on file with FDA and has received FDA approval at its GMP certified pilot plant to produce clinical grade product for Phase Ib clinical trials.
ART is applying SBIR grants to NCI with Sanford Research Center support to expand VACNO for conjunctive use with immunotherapy as a sixth (6th) therapeutic mechanism. ART has received HonorHealth support to apply for Phase Ib clinical trial funding from NCI. Private venture capital match funding towards the completion of Phase II Clinical Trials is being pursued.